Immunosuppressive therapy after human lung transplantation.

Area of Science:

• Immunology
• Transplantation Medicine
• Pharmacology

Background:

• Lung transplantation (LTx) outcomes are influenced by induction and maintenance immunosuppression.
• In 2002, LTx utilized induction therapy with antilymphocyte antibodies, anti-CD3, or anti-IL-2 receptor antibodies, with equal usage of induction vs. no induction.
• Maintenance regimens commonly involve a calcineurin inhibitor, cell-cycle inhibitor, and steroids, with a trend towards tacrolimus (Tac) over cyclosporin A (CsA) and mycophenolate mofetil (MMF) over azathioprine (Aza).

Purpose of the Study:

• To evaluate the long-term efficacy and safety of induction therapy in lung transplantation.
• To assess the impact of different maintenance immunosuppression strategies on graft and patient survival.
• To review current treatment approaches for refractory acute and chronic rejection post-LTx.

Main Methods:

• Retrospective analysis of LTx cases from 2002 comparing induction therapy versus no induction.
• Review of maintenance immunosuppression regimens, including calcineurin inhibitors (CsA, Tac), MMF, and Aza.
• Analysis of treatment strategies for acute and chronic rejection.

Main Results:

• The long-term benefit or harm of induction therapy in LTx remains undetermined.
• No established superiority of Tac over CsA for maintenance immunosuppression.
• A recent trial indicated MMF did not improve survival compared to Aza in combination with CsA and steroids.
• Switching from CsA to Tac is a primary strategy for refractory acute rejection.

Conclusions:

• The role of induction therapy in lung transplantation requires further investigation.
• Current maintenance immunosuppression protocols, including newer agents like MMF, have not demonstrated improved long-term survival benefits.
• Management of chronic rejection remains challenging, necessitating diverse therapeutic strategies.